ArticleJournal of cellular and molecular medicine2026
Tumour Necrosis Factor-α Promotes Pyroptosis in Diabetic Liver Injury via the HMGB1/TLR4/MyD88/NF-κB Pathway.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Diabetic liver injury (DLI) is a serious inflammatory complication, with tumour necrosis factor-alpha (TNF-α) recognized as a key pro-inflammatory cytokine. This study aimed to investigate the protective effect of TNF-α inhibition on DLI and to elucidate the underlying molecular mechanisms, focusing on the novel role of pyroptosis. An integrated experimental approach was employed, commencing with in vitro studies in HepG2 hepatocytes to dissect the signalling pathway, followed by in vivo validation in Sprague-Dawley rats. In vitro assessments included the expression of pyroptosis-related proteins (caspase1, Gasdermin D [GSDMD]), high mobility group protein B1 (HMGB1), and components of the Toll-like receptor 4 (TLR4)/myeloid differentiation factor 88 (MyD88)/nuclear factor-κB (NF-κB) pathway under high glucose conditions with or without TNF-α inhibition. In vivo measurements comprised liver function tests alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), triglycerides (TG), liver histopathology, and analysis of the HMGB1/TLR4/MyD88/NF-κB pyroptosis axis in liver tissues. In vitro, TNF-α inhibition mitigated high glucose-induced hepatocyte pyroptosis and suppressed HMGB1 release and TLR4/MyD88/NF-κB signalling; pharmacological blockade of HMGB1 replicated these effects. In vivo, recombinant human TNF receptor-II:Fc fusion protein (rhTNFR:Fc) significantly improved liver function and histopathology in diabetic rats without affecting blood glucose levels, while also downregulating the expression of HMGB1/TLR4/MyD88/NF-κB pathway components and key pyroptosis markers such as NOD-like receptor family pyrin domain containing 3 (NLRP3). In conclusion, TNF-α promotes DLI by driving hepatocyte pyroptosis through the HMGB1/TLR4/MyD88/NF-κB signalling axis. Inhibition of TNF-α confers potent hepatic protection independent of glycemic control, identifying it as a promising therapeutic strategy for DLI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.